NFKB1 and metabolic dysfunction-associated steatohepatitis: GSG can exert lipid-lowering, anti-inflammatory and delayed liver fibrosis therapeutic effects on NASH by inhibiting the conduction of NF-κB/IκB signaling pathway and their downstream inflammatory and apoptosis signaling.